Expedition Therapeutics
Latest round
- Series B
Last raised
- Aug 2026
Total raised
- $280M
Investors
- 14
About Expedition Therapeutics
Founded in 2024, based in California, US, Expedition Therapeutics Inc. operates a biotechnology company focused on developing targeted therapies for cancer. Leveraging advanced molecular profiling and translational research, the firm aims to deliver precision oncology solutions that improve patient outcomes. Its mission centers on innovation, collaboration, and accelerating the path from discovery to clinical impact. The company was founded by Yi Larson (CEO). In August 2026, Expedition Therapeutics Inc. Expedition Therapeutics focuses on developing innovative treatments specifically targeting inflammatory and respiratory diseases, primarily chronic obstructive pulmonary disease (COPD). Their lead product, EXPD-101, is an oral DPP1 inhibitor designed to address neutrophilic inflammation—an underlying mechanism that exacerbates tissue damage and lung function decline in COPD patients. The therapy aims to provide a disease-controlling option for nearly 70% of COPD patients who currently lack effective treatment alternatives. Additionally, the company is exploring the potential of EXPD-101 in related conditions such as bronchiectasis and neutrophilic asthma, thereby broadening its applicability. Expedition Therapeutics targets both the North American and European markets, seeking to deliver its advanced therapeutic solutions to a wide range of healthcare providers and patients globally. Revenue generation primarily revolves around partnerships and collaborations with pharmaceutical companies, healthcare providers, and research institutions that seek to leverage their innovative therapies. The transactions are expected to be structured around licensing agreements, clinical trial collaborations, and potentially direct sales once products receive regulatory approval and market entry. Flagship product EXPD-101 is anticipated to be central to these revenue streams, as it transitions into further clinical trials and prepares for commercialization.
Who invested in Expedition Therapeutics
14 investors across 3 rounds
See all investors in Expedition Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Expedition Therapeutics
Who invested in Expedition Therapeutics?
Expedition Therapeutics has 14 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Expedition Therapeutics raised?
Expedition Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Expedition Therapeutics last raise money?
Expedition Therapeutics's most recent round on record is a Series B, in Aug 2026.
What does Expedition Therapeutics do?
Founded in 2024, based in California, US, Expedition Therapeutics Inc.
Where is Expedition Therapeutics headquartered?
Expedition Therapeutics is headquartered in San Francisco, US.
Which VCs invest in companies like Expedition Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Expedition Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Expedition Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.